|

Everolimus Clinical Trials

26 actively recruiting trials across 10 locations

▼ -1 trial since August 2026

Also known as: 42-O-(2-Hydroxy)ethyl Rapamycin, AFINITOR, Afinitor, Afinitor®, Certican +9 more

Pipeline

Early 1: 1Phase 1: 2Phase 2: 9Phase 3: 6Phase 4: 1Phase 1/2: 3Phase 2/3: 2

Top Sponsors

  • National Cancer Institute (NCI)2
  • M.D. Anderson Cancer Center2
  • Gustave Roussy, Cancer Campus, Grand Paris2
  • West China Hospital1
  • University of Cincinnati1

Indications

Other11 trials

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Phase 3
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Phase 2
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
Phase 2
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Phase 3
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Phase 2
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
Pilot Trial for Treatment of Recurrent Glioblastoma
Early 1
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Phase 2/3
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2

Birmingham, Alabama4 trials

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

University of Alabama at Birmingham Cancer Center

Phase 2
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

University of Alabama at Birmingham, Children's of Alabama

Phase 1
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

The University of Alabama at Birmingham

Phase 2/3

Boston, Massachusetts2 trials

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Brigham and Women's Hospital

Phase 4
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Beth Israel Deaconess Medical Center ( Site 0107)

Phase 3

Houston, Texas2 trials

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

MD Anderson Cancer Center

Phase 1

Chandler, Arizona1 trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Ironwood Cancer & Research Centers

Phase 3

Phoenix, Arizona1 trial

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Research Facility

Phase 3

Duarte, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2

Stanford, California1 trial

Safety and Durability of Sirolimus for Treatment of LAM

Stanford University Medical Center

Aurora, Colorado1 trial

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Children's Hospital Colorado

Phase 2

New Haven, Connecticut1 trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Yale School of Medicine

Phase 1/2

Lebanon, New Hampshire1 trial

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Dartmouth Hitchcock Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.